Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever

Nilüfer Alpay; Abdullah Sumnu; Yaşar Calışkan; Halil Yazıcı; Aydın Türkmen; Ahmet Gül

doi:10.1007/s00296-010-1474-6

Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever

Rheumatol Int. 2012 Oct;32(10):3277-9. doi: 10.1007/s00296-010-1474-6. Epub 2010 Apr 13.

Authors

Nilüfer Alpay¹, Abdullah Sumnu, Yaşar Calışkan, Halil Yazıcı, Aydın Türkmen, Ahmet Gül

Affiliation

¹ Department of Internal Medicine, Istanbul School of Medicine, Istanbul University, Capa, Istanbul, Turkey. nalpay@istanbul.edu.tr

PMID: 20386914
DOI: 10.1007/s00296-010-1474-6

Abstract

Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by self-limited recurrent attacks of fever and serositis. The serious complication of FMF is AA-type amyloidosis, which can result in end-stage renal disease. Although colchicine is effective in the majority of patients, there is no established treatment for those who are resistant or intolerant to colchicine. We herein report the efficacy of anakinra in a 52-year-old Turkish patient with FMF, secondary amyloidosis and renal transplant, who was resistant to colchicine treatment.

Publication types

Case Reports

MeSH terms

Amyloidosis / etiology
Amyloidosis / therapy
Anti-Inflammatory Agents / therapeutic use*
Colchicine / therapeutic use*
Drug Resistance*
Familial Mediterranean Fever / complications
Familial Mediterranean Fever / diagnosis
Familial Mediterranean Fever / drug therapy*
Female
Humans
Interleukin 1 Receptor Antagonist Protein / therapeutic use*
Kidney Failure, Chronic / etiology
Kidney Failure, Chronic / surgery
Kidney Transplantation
Middle Aged
Treatment Failure

Substances

Anti-Inflammatory Agents
Interleukin 1 Receptor Antagonist Protein
Colchicine